AIM ImmunoTech Inc. Converts $450K Debt into 1.92M Common Shares

What Happened AIM ImmunoTech Inc. announced on Form 8-K that on September 3 and September 4, 2026 it entered into two exchange agreements (and corresponding partitioned promissory notes) with Streeterville Capital, LLC to convert approximately $450,000 of an existing promissory note (dated November 18, 2025) into common stock. The conversions resulted in issuance of a total of 1,921,441 shares of common stock at an average conversion price of about $0.234 per share. The conversion had been approved by AIM stockholders at a special meeting on July 15, 2026 in accordance with NYSE American Company Guide Sections 713(a) and 713(b).

Key Details

• Lender: Streeterville Capital, LLC.
• Dates of agreements: September 3, 2026 and September 4, 2026.
• Debt converted: approximately $450,000 of the Promissory Note (originally dated November 18, 2025).
• Shares issued: 1,921,441 common shares at an average conversion price of ≈ $0.234/share.
• Stockholder approval: Special meeting on July 15, 2026 under NYSE American rules.

Why It Matters This transaction reduces the company’s outstanding debt obligation by about $450,000 and increases the number of common shares outstanding by roughly 1.92 million, which is a dilutive event for existing shareholders. The conversion was completed under previously obtained stockholder authorization, meaning the issuance complied with NYSE American approval requirements. Investors should note the dual impact on the balance sheet (lower debt, higher equity) and consider the effect of the additional shares on per-share metrics.